Issue Date: May 24, 2010
Merck In Heart Drug Deal With ElexoPharm
Merck & Co. and German contract research organization ElexoPharm will work together to develop novel drug candidates targeting aldosterone synthase for the treatment of cardiovascular disease. ElexoPharm scores $1.9 million up front and could receive another $40 million in milestones throughout the course of the pact. ElexoPharm was spun out of Saarland University’s department of pharmaceutical and medicinal chemistry in 2005.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society